IPI-549 + Opdivo is a small molecule commercialized by Infinity Pharmaceuticals, with a leading Phase II program in Metastatic Transitional (Urothelial) Tract Cancer. According to Globaldata, it is involved in 7 clinical trials, of which 2 were completed, 3 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of IPI-549 + Opdivo’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for IPI-549 + Opdivo is expected to reach an annual total of $105 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
IPI-549 + Opdivo Overview
IPI-549 is under development for the treatment of solid tumors including metastatic renal cell cancer, soft tissue sarcoma and prostate cancer, triple negative breast cancer, colon cancer, metastatic melanoma, non-small cell lung cancer, glioblastoma multiforme, microsatellite-stable gallbladder carcinoma, head and neck cancer squamous cell carcinoma, mesothelioma, ovarian cancer, adrenocortical carcinoma and metastatic urothelial cancer including renal pelvis cancer, ureter cancer, bladder cancer, urethra cancer. The drug candidate is administered through oral route. It acts by targeting phosphoinositide-3-kinase gamma (PI3K-gamma). It was also under development for the treatment of metastatic ovarian cancer.
Infinity Pharmaceuticals Overview
Infinity Pharmaceuticals is a biopharmaceutical company which discovers and develops small molecule therapeutics for the treatment of cancer. The company’s pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and transforms immuno-oncology approach. The company is evaluating IPI-549 as a monotherapy and in a combination therapy in various clinical trials for the treatment of various indications such advanced solid tumors, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC), mesothelioma, and myeloid-derived suppressor cells (MDSC). The company has collaborations with other biopharmaceuticals companies for the development of its pipeline programs. Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$1.9 million for the fiscal year ended December 2021 (FY2021), an increase of 8.1% over FY2020. The operating loss of the company was US$45.1 million in FY2021, compared to an operating loss of US$38.5 million in FY2020. The net loss of the company was US$45.3 million in FY2021, compared to a net loss of US$40.5 million in FY2020. The company reported revenues of US$0.7 million for the third quarter ended September 2022, an increase of 3.8% over the previous quarter.
For a complete picture of IPI-549 + Opdivo’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.